- The Medicines Company stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
The Medicines Company stock price
The Medicines Company latest news:
CORRECTED-Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER
Jan 12 (Reuters) - The proposed price for Spark Therapeutics
Inc's groundbreaking one-time gene therapy for a rare
form of blindness is far too high, an independent U.S. nonprofit
organization that evaluates clinical and cost effectiveness of
new medicines said on Friday.
Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER
The proposed price for Spark Therapeutics Inc's (ONCE) groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics
Melinta Therapeutics, Inc.(MLNT): * THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING Source text: Further company coverage:
BRIEF-Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency
* HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS
RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES
AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
Source text for Eikon:
Further company coverage:
UK Stocks-Factors to watch on Jan 9
Jan 9 (Reuters) - Britain's FTSE 100 index is seen opening up 11
points on Tuesday, according to financial bookmakers.
* SHIRE: Shire ditched its revenue target of $20 billion by 2020 on
Monday due to increased generic competition and new drugs from rivals, saying it
would split its rare disease and hyperactivity medicines businesses to boost
* PSA JOBS: Peugeot-maker PSA will cut a further 250 jobs at its
Vauxhall car plant in the north of England, reducing the wor
Health-care ETF tumbles as biotechnology stocks weigh
The largest exchange-traded fund to track the health-care sector fell on Monday, dropping as the biggest declining industry of the day by far. The Health Care Select Sector SPDR ETF was down 0.8%, its biggest one-day percentage drop since Dec. 14. The fund is coming off a four-day rally, and it hit a record on Friday. Biotechnology companies were the biggest drags on the sector on Monday. Celgene Corp. fell 3.2% after it agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion. Separately, Biogen Inc. shares fell 3.9% while those for Regeneron Pharmaceuticals was down 3.1%. The iShares Nasdaq Biotechnology ETF fell 0.8% on Monday. Thus far this year, the health-care fund is up 2.3%, compared with the 2.6% rise of the S&P 500 . The S&P was unchanged in Monday trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Celgene to buy Impact Biomedicines for up to $7 billion
U.S. biotech pharmaceutical firm Celgene Corp (CELG) said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.
BRIEF-State Street Global Advisors Announces Impact Of Receiving Settlement Payment
State Street Corp(STT): * STATE STREET GLOBAL ADVISORS ANNOUNCES IMPACT OF RECEIVING SETTLEMENT PAYMENT. * SPDR EXCHANGE TRADED FUND - RECEIVED PAYMENT AS AUTHORIZED CLAIMANT FROM A CLASS ACTION SETTLEMENT RELATED TO MEDICINES COMPANY Source text for Eikon: Further company coverage:
Bumper crop of new drugs fails to lift big pharma R&D returns
* 41 FDA drug approvals so far in 2017 vs 22 for all 2016. * Biotech companies account for growing share. * Deloitte says big pharma returns on R&D just 3.2 percent. By Ben Hirschler. It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.
BRIEF-Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share
Blueprint Medicines Corp(BPMC): * BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK. * SAYS PUBLIC OFFERING OF 3.70 MILLION COMMON SHARES PRICED AT $81.00PER SHARE Source text for Eikon: Further company coverage:
BRIEF-Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
Blueprint Medicines Corp(BPMC): * BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK. * BLUEPRINT MEDICINES CORP SAYS IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $275.0 MILLION IN SHARES OF ITS COMMON STOCK. * BLUEPRINT MEDICINES-EXPECTS TO USE PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR AVAPRITINIB IN GASTROINTESTINAL STROMAL TUMORS,SYSTEMIC MASTOCYTOSIS.
Blueprint Medicines Wins Big in Early-Stage Trial
UPDATE: Medicines Co. agrees to sell infectious disease unit to Melinta Therapeutics
The Medicines Co. said Wednesday it has agreed to sell its infectious disease unit to Melinta Therapeutics Inc. for $270 million in upfront consideration, guaranteed payments of $215 million in cash and $55 million of Melinta common stock, as well as tiered royalty payments of 5% to 25% on sales of Vabomere, Orbactiv and Minocin IV. Clive Meanwell, Chief Executive of The Medicines Co., said the deal will allow the company to achieve three critical goals. The first is to provide the cash to advance inclisiran, a hypercholesterolaemia treatment, through a Phase III program in the second half of 2019 and associated manufacturing development. The second is to provide the resources to promote inclisiran, which the company believes has blockbuster potential, and the third to recognize the value of the three drugs mentioned above. The deal is expected to close in the first quarter. The Medicines Co. shares fell 5.7% in premarket trade. Melinta stock surged 6% after resuming trade following a halt. The stock has gained 7% in 2017 through Tuesday, while the S&P 500 has gained 17%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA
* AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR
MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE
DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY
Teva shares rise 4% on major reorganization, leadership changes
Teva Pharmaceutical Industries Ltd. shares rose 4% in Monday morning trade after the company announced a major reorganization and several top leadership changes. Cheap generic drug prices have put significant pressure on the generic drugmaker in recent months, and the changes -- under new Chief Executive Kare Schultz -- were described as a way to take "decisive and immediate action to address external pressures and internal inefficiencies," according to a statement by Schultz. Teva, which previously organized its generics and specialty drug businesses in two separate units, will now instead operate through three regions -- North America, Europe and Growth Markets -- that will manage all Teva drugs "with full end-to-end P&L accountability," the company said. Some of Teva's previous business units will be retained, but not all, Teva said. Leadership changes include the retirement of Michael Hayden, president of global research and development, Rob Koremans, president and chief executive of global specialty medicines, and Dipankar Bhattacharjee, president and chief executive officer of the global generic medicines group, at the end of the year. The company's new management team includes now-Chief Financial Officer and Executive Vice President Michael McClellan, Executive Vice President, Global R&D Hafrun Fridriksdottir, Executive Vice President, North America Commercial Brendan O'Grady, Executive Vice President, European Commercial Richard Daniell, Executive Vice President, Growth Markets Commercial Gianfranco Nazzi and Executive Vice President, Global Marketing & Portfolio Sven Dethlefs. Teva shares have dropped 13% over the last three months and 61% year-to-date, compared with a 6.5% rise in the S&P 500 over the last three months and a 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amsterdam wins bid to host EU medicines agency post-Brexit
EU ministers chose a new home for the European Medicines Agency, which is leaving the UK after Brexit.
AstraZeneca ticks another box as U.S. approves severe asthma drug
* FDA clears Fasenra for patients aged 12 years and older. * AstraZeneca (AZN) prices maintenance dose below rivals. * AstraZeneca (AZN) product will vie with GSK's Nucala. By Ben Hirschler. AstraZeneca (AZN) has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.
BRIEF-Arbutus’LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency
* Arbutus’ LNP Licensee Alnylam receives accelerated
patisiran from European Medicines Agency (EMA)
Source text for Eikon:
Further company coverage:
BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency
* Vanda receives negative opinion for marketing
the European Medicines Agency on fanaptum™ for the treatment of
The Michaels Companies, Inc.MIK
The Middleby CorporationMIDD
The Navigators Group, Inc.NAVG
The ONE Group Hospitality, Inc.STKS
The Priceline Group Inc. PCLN
The Providence Service CorporationPRSC
The Spectranetics CorporationSPNC
The Ultimate Software Group, Inc.ULTI
The York Water CompanyYORW